Skip to main content
NKMAX Co., Ltd. logo

NKMAX Co., Ltd. — Investor Relations & Filings

Ticker · 182400 ISIN · KR7182400002 KO Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 182400

About NKMAX Co., Ltd.

https://nkmax.com/

NKMAX Co., Ltd. is a biotechnology company focused on developing immune-based solutions centered on Natural Killer (NK) cells. The company's primary focus is the development of adoptive cell therapies to treat incurable diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. Its portfolio includes anti-cancer immunotherapy treatments and other biological products. In addition to therapeutics, NKMAX develops and markets a precision diagnostic test that measures NK cell activity. The company also manufactures and supplies specialized reagents, such as high-quality recombinant proteins and antibodies, for biotechnology research, as well as a line of health functional foods designed to support the immune system.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 92% confidence The document is titled “분기보고서” (quarterly report) covering the 25th fiscal period from January 1, 2026 to March 31, 2026. It is filed with the Financial Services Commission and the Korea Exchange and contains extensive company overview, business description, historical data, and actual financial statement schedules. It is a full interim/quarterly financial report, not merely a brief announcement or presentation. Therefore, it matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 88% confidence The document is a statutory ‘주식등의 대량보유상황보고서(일반)’ filed under the Korean Capital Markets Act (자본시장과 금융투자업에 관한 법률 제147조). It details the number and percentage of shares held, changes in holdings, related contracts, and threshold crossings by a major shareholder. This matches our definition for a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2026-04-22 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Regulatory Filings Classification · 75% confidence The document is a statutory correction (“정정신고”) of a prior disclosure regarding a collateral provision agreement in which the company’s major shareholder (NKGen Biotech, Inc.) has pledged its shares as security for debt. This is neither an earnings release, management or board change, nor an annual or interim financial report. It does not involve new share issuance or a buyback by the company (POS), nor a director’s personal trade (DIRS), nor does it change actual share ownership percentages (MRQ), and it is not a proxy, dividend, governance or ESG report. It is a standalone regulatory disclosure of a share pledge/collateral agreement, which does not fit any highly specific category. Therefore it falls into the fallback “Regulatory Filings” category (RNS).
2026-04-22 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 93% confidence The document is a statutory notification filed with the Korea Financial Services Commission and Korea Exchange regarding the appointment, reappointment, and resignation (dismissal) of an outside director (“사외이사 선임·해임·중도퇴임”). It details board composition changes and directors’ term dates. This is not a full report, not a trading transaction, and not a financial statement – it is clearly an announcement of changes in the company’s board of directors. According to the predefined categories, this maps to Board/Management Information (MANG).
2026-03-31 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is the official results of a regular shareholders’ (annual general) meeting held on 2026-03-31, listing each agenda item, vote counts, approval status, and detailed election results for directors and auditors. It is not an announcement of a report publication nor the full report itself, but the formal declaration of vote outcomes. This matches the definition for "Declaration of Voting Results & Voting Rights Announcements" (Code: DVA).
2026-03-31 Korean
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 95% confidence The document is a Korean regulatory filing notifying changes to outside directors (appointment, dismissal, mid‐term resignation) along with correction details. It is not a share trading report or dividend notice, but a Board/Management Information change (outside director). Therefore it fits the Board/Management Information category (MANG).
2026-03-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.